Table 1.

Patient demographics and clinical data

Patient Characteristics	Study Population	IBD	JIA	Uveitis
Patients, n	97	73	16	8
Gender, female, n (%)	43 (44)	29 (40)	10 (63)	4 (50)
Age, yr, median [range]	16 [5,21]	16 [5,21]	13 [7,20]	16 [6,21]
Diagnosis, n (%)
IBD	73 (75)
JIA	16 (17)
Uveitis	8 (8)
IFX Dosing, median [IQR]
Dose, mg/kg	8.4 [6.5,9.8]	7.7 [6.2,9.4]	9.7 [8.5,10.7]*	10.5 [7.5,12.0]#
Interval, weeks	6 [4,7]	6 [4,8]	4 [4,5]*	4 [4,6]#
Immunomodulator, n (%)
MTX	37 (38)	19 (26)	12 (75)*	6 (75)#
AZA	3 (3)	3 (4)	0 (0)	0 (0)
Inflammatory Markers, median [IQR]
ESR, mm/hr	9 [6,17.5]	9 [7,17]	7 [6,17]	13 [7,22]
CRP, mg/dL	0.5 [0.5,0.8]	0.5 [0.5,0.8]	0.5 [0.5,0.6]	0.7 [0.6,0.8]
Albumin, g/dL	4.3 [4.0,4.5]	4.3 [4.0,4.5]	4.3 [4.2,4.6]	4.3 [4.0,4.6]

*, IBD vs JIA, significant at p < 0.05

#, IBD vs Uveitis, significant at p < 0.05